Buy Day today: Good (67) Broad market participation · no major macro event

Halozyme Therapeutics Inc (HALO)

Healthcare Biotechnology

82.30 $

-0.3% vs. previous close

Closing price · As of: 3. Aug 2026

Halozyme Therapeutics Inc (HALO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Revenue" came in at 377 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow

Annual Quarterly

All figures in millions of USD.

Income Statement HALO
Tick rows to compare them in a chart (up to 4)	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	LTM
Revenue	221	216	230	196	231	290	298	265	326	354	452	377	1,508
Cost of Revenue	50	55	52	46	57	49	42	66	64	73	102	109	348
Gross Profit	171	161	178	150	174	241	256	199	262	281	350	268	1,160
Research & Development	20	17	21	19	21	18	20	15	18	17	32	26	92
Selling, General & Administrative	39	35	38	35	36	41	42	42	42	46	77	58	223
Total Operating Expenses	77	73	77	54	57	77	80	57	59	63	95	83	301
Operating Income	94	88	101	96	117	163	176	142	202	218	254	185	859
Interest Expense	4.5	4.5	5.2	4.5	4.5	4.5	4.5	4.5	4.4	4.3	4.9	5.5	19
Pre-Tax Income	93	102	101	96	118	165	178	144	205	219	-101	180	503
Income Tax Expense	18	20	16	19	24	28	41	26	40	44	41	30	155
Net Income	75	82	85	77	93	137	137	118	165	175	-142	150	349
EBITDA	118	129	127	121	143	190	203	169	230	244	-69	220	624

LTM = last twelve months (sum of the four most recent quarters).

Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Cookie settings